Gibson, Dunn & Crutcher and White & Case have emerged as the foremost legal advisers for mergers and acquisitions (M&A) in ...

Merck KGaA could now have a head start in the race to market Precem-TcT, which could become the first widely approved ADC in ...

Merck's (MSD) $3bn Virginia facility is part of the big pharma's $70bn US R&D and manufacturing expansion pledge.

At AAO 2025, EyePoint Pharmaceuticals presented updates on its investigational therapy EYP-1901 (vorolanib) for DME and wAMD.

The complex and costly journey of oncology drug development is reliant on robust and comprehensive clinical data. Early-stage ...

H. Lundbeck and Contera Pharma have announced a research partnership in new oligonucleotide-based therapies for neurological ...

The US FDA has granted approval for Roche's Gazyva/ Gazyvaro to treat adult patients with active LN who are on standard ...

Dermatology is thriving with innovation, from smart oral drugs to gene-therapy based fixes for rare skin diseases and skin ...

Morgan Stanley has secured the leading position as a financial adviser by deal value in South & Central America's M&A sector.

JP Morgan and Rothschild & Co have emerged as the top mergers and acquisitions (M&A) financial advisers in the Middle East & ...

In the realm of M&A, Skadden, Arps, Slate, Meagher & Flom, and Veirano Advogados have emerged as the top legal advisers in ...

These Phase III results could enhance uptake of Eli Lilly's Verzenio alongside ET in the adjuvant breast cancer setting, if ...